Evotec AG hopes that buying Germany-based Bionamics GmbH will let it profitably bridge the gap between academic research projects and industry’s need for preclinical and clinical development programs, especially in the arena of neurodegenerative diseases.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?